What happened
SK Bioscience filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$110M (−3.8% year on year), an operating loss of US$11.1M and a net loss of US$9.94M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$110M |
|---|---|
| Revenue vs a year earlier | −3.8% |
| Operating profit | −US$11.1M |
| Net income | −US$9.94M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-08-10, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260810800429 → open original filing |
Source: DART. Information only, not investment advice.